JP2017520527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520527A5 JP2017520527A5 JP2016567824A JP2016567824A JP2017520527A5 JP 2017520527 A5 JP2017520527 A5 JP 2017520527A5 JP 2016567824 A JP2016567824 A JP 2016567824A JP 2016567824 A JP2016567824 A JP 2016567824A JP 2017520527 A5 JP2017520527 A5 JP 2017520527A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- compound
- diabetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000010837 Diabetic eye disease Diseases 0.000 claims 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- LUUMLYXKTPBTQR-UHFFFAOYSA-N 4-chloro-n-[5-methyl-2-(7h-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C(C)=CN=C(C(=O)C=2C=3C=CNC=3N=CN=2)C=1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 LUUMLYXKTPBTQR-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 101150052909 CCL2 gene Proteins 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 101100495315 Dictyostelium discoideum cdk5 gene Proteins 0.000 claims 1
- 101100399297 Dictyostelium discoideum limE gene Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 101150050263 ICAM1 gene Proteins 0.000 claims 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 101150097457 Vcam1 gene Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000004900 autophagic degradation Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000004637 cellular stress Effects 0.000 claims 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 1
- 229960002286 clodronic acid Drugs 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 101150006779 crp gene Proteins 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000003345 hyperglycaemic effect Effects 0.000 claims 1
- NBGMRMDAEWWFIR-UHFFFAOYSA-N imidazole-2-thione Chemical compound S=C1N=CC=N1 NBGMRMDAEWWFIR-UHFFFAOYSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- PWDYHMBTPGXCSN-VCBMUGGBSA-N n,n'-bis[3,5-bis[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]decanediamide Chemical compound NC(N)=N/N=C(\C)C1=CC(C(=N/N=C(N)N)/C)=CC(NC(=O)CCCCCCCCC(=O)NC=2C=C(C=C(C=2)C(\C)=N\N=C(N)N)C(\C)=N\N=C(N)N)=C1 PWDYHMBTPGXCSN-VCBMUGGBSA-N 0.000 claims 1
- IBPXYDUJQWENPM-PKTZIBPZSA-N n-[2-[[(1r,2s)-2-[(4-methylsulfanylbenzoyl)amino]cyclohexyl]amino]-2-oxoethyl]-2-(propan-2-ylcarbamoylamino)-5-(trifluoromethyl)benzamide Chemical compound C1=CC(SC)=CC=C1C(=O)N[C@@H]1[C@H](NC(=O)CNC(=O)C=2C(=CC=C(C=2)C(F)(F)F)NC(=O)NC(C)C)CCCC1 IBPXYDUJQWENPM-PKTZIBPZSA-N 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229950011005 semapimod Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993915P | 2014-05-15 | 2014-05-15 | |
| US61/993,915 | 2014-05-15 | ||
| US201462064344P | 2014-10-15 | 2014-10-15 | |
| US62/064,344 | 2014-10-15 | ||
| US201462076162P | 2014-11-06 | 2014-11-06 | |
| US62/076,162 | 2014-11-06 | ||
| US201562157773P | 2015-05-06 | 2015-05-06 | |
| US62/157,773 | 2015-05-06 | ||
| PCT/IB2015/053609 WO2015173786A1 (en) | 2014-05-15 | 2015-05-15 | Compositions and methods for treating and diagnosing ocular disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520527A JP2017520527A (ja) | 2017-07-27 |
| JP2017520527A5 true JP2017520527A5 (enExample) | 2018-06-28 |
| JP6625064B2 JP6625064B2 (ja) | 2019-12-25 |
Family
ID=54479391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567824A Active JP6625064B2 (ja) | 2014-05-15 | 2015-05-15 | 眼障害を治療かつ診断するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20170079955A1 (enExample) |
| EP (1) | EP3142664B1 (enExample) |
| JP (1) | JP6625064B2 (enExample) |
| DK (1) | DK3142664T3 (enExample) |
| ES (1) | ES2789849T3 (enExample) |
| HU (1) | HUE049518T2 (enExample) |
| WO (1) | WO2015173786A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| CA3040419A1 (en) | 2016-10-13 | 2018-04-19 | Translatum Medicus, Inc. | Systems and methods for detection of ocular disease |
| WO2018119202A1 (en) * | 2016-12-23 | 2018-06-28 | StemBios Technologies, Inc. | Use of somatic stem cells for increasing level of peroxisome proliferator-activated receptor gamma |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| RU2683758C1 (ru) * | 2018-06-27 | 2019-04-01 | Федеральное государственное учреждение "Федеральный исследовательский центр "Информатика и управление" Российской академии наук" (ФИЦ ИУ РАН) | Автоматизированная система анализа ангиографических изображений глазного дна человека |
| EP3706136A1 (en) * | 2019-03-05 | 2020-09-09 | Novartis AG | Computerized systems for prediction of geographic atrophy progression using deep learning applied to clinical imaging |
| US11753382B2 (en) | 2019-06-25 | 2023-09-12 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| RU196414U1 (ru) * | 2019-12-23 | 2020-02-28 | Федеральное государственное учреждение "Федеральный исследовательский центр "Информатика и управление" Российской Академии Наук" | Анализатор ангиографических изображений глазного дна человека |
| GB202001336D0 (en) * | 2020-01-31 | 2020-03-18 | Imp College Innovations Ltd | Methods for measuring gut permeability and gastric emptying rate |
| JP2025512467A (ja) * | 2022-04-14 | 2025-04-17 | ビーライト バイオ，インク | 視覚機能の評価のための方法、組成物およびシステム |
| EP4662203A1 (en) * | 2023-02-10 | 2025-12-17 | Translatum Medicus Inc. | Bindarit conjugates, compositions and methods for treating ocular diseases or disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| WO2005108431A1 (en) * | 2004-05-04 | 2005-11-17 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of ocular neovascularization |
| ITMI20062254A1 (it) * | 2006-11-24 | 2008-05-25 | Acraf | Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca |
| LT2254869T (lt) * | 2008-03-07 | 2017-08-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška |
| CN104334173B (zh) * | 2012-05-01 | 2017-05-03 | 特兰斯拉图姆医学公司 | 用于治疗和诊断致盲性眼病的方法 |
-
2015
- 2015-05-15 WO PCT/IB2015/053609 patent/WO2015173786A1/en not_active Ceased
- 2015-05-15 JP JP2016567824A patent/JP6625064B2/ja active Active
- 2015-05-15 HU HUE15792756A patent/HUE049518T2/hu unknown
- 2015-05-15 US US15/311,083 patent/US20170079955A1/en not_active Abandoned
- 2015-05-15 ES ES15792756T patent/ES2789849T3/es active Active
- 2015-05-15 EP EP15792756.7A patent/EP3142664B1/en active Active
- 2015-05-15 DK DK15792756.7T patent/DK3142664T3/da active
-
2018
- 2018-05-30 US US15/993,183 patent/US20180338952A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017520527A5 (enExample) | ||
| JP7475395B2 (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| ES2892954T3 (es) | Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos | |
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| RU2015117536A (ru) | Vegf-нейтрализирующие пролекарства для лечения офтальмологических заболеваний | |
| JP2008538215A5 (enExample) | ||
| JP2016519680A5 (enExample) | ||
| JP6466504B2 (ja) | 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト | |
| JP2015025011A5 (enExample) | ||
| TW201136915A (en) | Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization | |
| JP2014533274A5 (enExample) | ||
| JP2014506582A5 (enExample) | ||
| JP2020531511A5 (enExample) | ||
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| JP6267003B2 (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| JP2013510852A (ja) | フルオレノン誘導体による眼の病態の治療 | |
| CN106604730A (zh) | 角膜厚度调节剂 | |
| JP2007527417A5 (enExample) | ||
| RU2015145134A (ru) | Местное лечение воспалительных офтальмологических заболеваний | |
| CN110114066B (zh) | 含沙丁胺醇的眼科药物 | |
| RU2020119228A (ru) | Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи | |
| JP2021138710A5 (enExample) | ||
| JP2020511437A5 (enExample) | ||
| JP2011527286A5 (enExample) |